Reduced intensity conditioning (RIC)
Showing 1 - 25 of >10,000
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies Trial in Philadelphia (RIC: Distal Campath, RIC:Intermediate
Recruiting
- Non Malignant Diseases
- +2 more
- RIC: Distal Campath
- +2 more
-
Philadelphia, PennsylvaniaThe Children's Hospital of Philadelphia
Mar 8, 2022
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplant (HSCT) Trial in Pittsburgh
Active, not recruiting
- Acute Myeloid Leukemia (AML)
- +2 more
- Reduced-Intensity Conditioning Regimen
- Myeloablative Conditioning Regimen
-
Pittsburgh, PennsylvaniaUPMC Children's Hospital of Pittsburgh
Jan 4, 2023
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders Trial in Minneapolis (Blood and Marrow Transplant)
Recruiting
- Sickle Cell Disease
- +4 more
- Blood and Marrow Transplant
-
Minneapolis, MinnesotaMasonic Caner Center at University of Minnesota
May 23, 2022
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)
Completed
- Acute Myelogenous Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Jan 4, 2023
Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies Trial in Minneapolis (drug, radiation, biological)
Recruiting
- Hematologic Disorders
- +2 more
- Busulfan
- +4 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Jul 12, 2021
Hematologic Malignancies Trial in Minneapolis (Haplo HCT <55 years old, Haplo HCT =55 years old, GVHD Prophylaxis)
Recruiting
- Hematologic Malignancies
- Haplo HCT <55 years old
- +4 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Jan 25, 2023
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia Trial in Minneapolis (biological, drug,
Not yet recruiting
- Acute Myelogenous Leukemia
- +17 more
- Peripheral Blood Stem Cell Transplant
- +7 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Mar 27, 2023
Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation Trial in Shanghai (Venetoclax plus RIC)
Not yet recruiting
- Leukemia, Myeloid, Acute
- +3 more
- Venetoclax plus RIC
-
Shanghai, Shanghai, ChinaShanghai General Hospital
Oct 12, 2022
Graft Vs Host Disease Trial in United States (PRO 140)
Terminated
- Graft Vs Host Disease
- PRO 140
-
Miami, Florida
- +7 more
Jan 13, 2022
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders Trial in New Haven, Saint Louis (RIC regimen,
Recruiting
- Severe Sickle Cell Disease
- +5 more
- RIC regimen
- GVHD prophylaxis regimen
-
New Haven, Connecticut
- +1 more
Feb 4, 2022
Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Recruiting
- Primary Immunodeficiency (PID)
- +4 more
- data collection
-
Pittsburgh, PennsylvaniaUPMC Children's Hospital of Pittsburgh
Feb 9, 2022
Acute Myeloid Leukemia in Remission Trial in France (Fludarabine, Busulfan, ATG)
Not yet recruiting
- Acute Myeloid Leukemia in Remission
- Fludarabine
- +3 more
-
Nantes, Loire Atlantique, France
- +22 more
Jun 15, 2023
Hematologic Malignancy, Haplo-identical Stem Cell Transplantation Trial (CD45RAneg cells, prepared from mononuclear cell
Not yet recruiting
- Hematologic Malignancy
- Haplo-identical Stem Cell Transplantation
- CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
- (no location specified)
Oct 1, 2021
Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation Trial in Wuhan
Recruiting
- Acute Myeloid Leukemia, Adult
- +2 more
- Fludarabine and Busulfan
- Fludarabine and Melphalan
-
Wuhan, Hubei, ChinaWuhan Union Hospital, Tongji Medical college, Huazhong Universit
Jan 5, 2023
Refractory Leukemia Trial in Shanghai (CALGE-VEN- RIC-MBF)
Recruiting
- Refractory Leukemia
- CALGE-VEN- RIC-MBF
-
Shanghai, Shanghai, China
- +2 more
May 22, 2023
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia Trial in Minneapolis (drug, radiation,
Recruiting
- Acute Myelogenous Leukemia
- +17 more
- Allopurinol
- +8 more
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
May 21, 2021
Myelofibrosis Trial in Italy (A: Fludarabine + Busulphan, B: Fludarabine + Thiotepa)
Completed
- Myelofibrosis
- A: Fludarabine + Busulphan
- B: Fludarabine + Thiotepa
-
Alessandria, Italy
- +20 more
Aug 19, 2021
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,
Recruiting
- Primary Immune Deficiency Disorder
- +2 more
- Alemtuzumab
- +6 more
-
Baltimore, MarylandJohns Hopkins University
Oct 20, 2022
Acute Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma Trial in Marseille (Hematopoietic stem cells transplantation)
Active, not recruiting
- Acute Leukemia
- +2 more
- Hematopoietic stem cells transplantation
-
Marseille, FranceInstitut Paoli-Calmettes
Mar 26, 2021
Hematological Malignancy, Leukemia, Multiple Myeloma Trial in Milwaukee (Evomela, Fludarabine, Total Body Irradiation)
Recruiting
- Hematological Malignancy
- Multiple Myeloma
- Evomela
- +2 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Oct 4, 2022
Acute Lymphoblastic Leukemia Trial in United Kingdom (Fludarabine, Melphalan, Alemtuzumab)
Recruiting
- Acute Lymphoblastic Leukemia
- Fludarabine
- +5 more
-
Birmingham, United Kingdom
- +21 more
Oct 14, 2021
Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Worldwide (Busulfan, Treosulfan)
Completed
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
-
Helsinki, Finland
- +32 more
Jul 29, 2020